Two main peptide strategies
Growth hormone (GH) release can be stimulated via the GHRH receptor (hypothalamic pathway) or the ghrelin receptor GHS-R1a (GHRP / ghrelin-mimetic pathway). Educational comparisons start there: sermorelin and CJC-1295-class molecules speak GHRH language; GHRP-2, GHRP-6, hexarelin, and ipamorelin speak ghrelin-receptor language.
GHRH analogs: sermorelin and CJC-1295
Sermorelin is essentially GHRH (1-29). CJC-1295 variants extend half-life concepts (including DAC albumin-binding ideas in some versions). Readers often confuse “CJC-1295 with DAC” and “modified GRF 1-29 / without DAC”—names in the marketplace are inconsistent, so mass and sequence confirmation matter.
GHRPs and selectivity
Early GHRPs can influence cortisol and prolactin in some contexts; ipamorelin is frequently described as more selective. That selectivity story is a major reason for its popularity in secondary literature and forums.
Why MK-677 appears in the same searches
MK-677 (ibutamoren) is an oral ghrelin-receptor agonist small molecule, not a peptide. Search engines and users group it with peptide secretagogues because the receptor pathway overlaps.
Research design notes
GH-axis experiments must account for pulsatility, feedback via IGF-1, sleep and nutrition confounds, and assay timing. Single time-point GH measurements can mislead. Educational content should model scientific humility.
FAQ
What is CJC-1295 with DAC?+
It refers to a long-acting GHRH-analog design using a Drug Affinity Complex intended to bind albumin and extend half-life. Marketplace naming varies—verify identity analytically.
Ipamorelin vs GHRP-6?+
Both are GHS-R agonists; ipamorelin is often described as more selective, while GHRP-6 is associated with stronger orexigenic signaling in many discussions. Primary literature should guide experimental choices.